Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.

Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, Concepcion RS, Paivanas TA, van Breda A, Beebe-Dimmer J, Ruterbusch JJ, Wissmueller S, Campbell DH, Walsh BJ.

Oncotarget. 2018 Apr 27;9(32):22359-22367. doi: 10.18632/oncotarget.25009. eCollection 2018 Apr 27.


Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting.

White J, Shenoy BV, Tutrone RF, Karsh LI, Saltzstein DR, Harmon WJ, Broyles DL, Roddy TE, Lofaro LR, Paoli CJ, Denham D, Reynolds MA.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):78-84. doi: 10.1038/s41391-017-0008-7. Epub 2017 Nov 20.


A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.

Gee JR, Saltzstein DR, Kim K, Kolesar J, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House MG, Parnes HL, Bailey HH.

Cancer Prev Res (Phila). 2017 May;10(5):298-307. doi: 10.1158/1940-6207.CAPR-16-0167. Epub 2017 Mar 21.


Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.

Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH.

Eur J Cancer Prev. 2016 Jul;25(4):312-20. doi: 10.1097/CEJ.0000000000000189.


A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM.

Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27.


A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H.

Cancer Prev Res (Phila). 2012 Apr;5(4):621-30. doi: 10.1158/1940-6207.CAPR-11-0455. Epub 2012 Jan 31.


The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.

Clin Genitourin Cancer. 2007 Mar;5(4):271-7.


Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.

Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, Sanders SW; Transdermal Oxybutynin Study Group.

J Urol. 2002 Aug;168(2):580-6.


Failure of the polymerase chain reaction (PCR) to detect human papilloma virus (HPV) in transitional cell carcinoma of the bladder.

Saltzstein DR, Orihuela E, Kocurek JN, Payne DA, Chan TS, Tyring SK.

Anticancer Res. 1993 Mar-Apr;13(2):423-5.


Balloon ureteral occlusion: a new reversible technique in the management of ureteral fistulas.

Saltzstein DR, Orihuela E, Reed J.

J Urol. 1992 Feb;147(2):407-8. No abstract available.


Nondilated obstructive uropathy and renal failure as a result of carcinoma of the intrapelvic area.

Kocurek JN, Orihuela E, Saltzstein DR.

Surg Gynecol Obstet. 1991 Dec;173(6):470-2. Review.


Supplemental Content

Loading ...
Support Center